AngioDynamics Inc (ANGO)
AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025
Revvity Inc. (RVTY)
Revvity - Revvity to Hold Earnings Call on Monday, July 28, 2025
Alterity Therapeutics Limited (ATHE)
Semler Scientific Inc (SMLR)
Alcon AG (ALC)
Alcon - Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
Allurion Technologies Inc (ALUR)
Allurion - Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints
Urogen Pharma Inc (URGN)
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Allurion Technologies Inc (ALUR)
Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints
Allarity Therapeutics Inc. (ALLR)
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
Alcon AG (ALC)
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
Artelo Biosciences Inc. (ARTL)
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
Artelo Biosciences Inc. (ARTLW)
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
GSK plc (GLAXF)
Jasper Therapeutics Inc. (JSPRW)
Mallinckrodt PLC (MNKTQ)
New Form 8-K - Mallinckrodt plc Filed: 2025-07-07 AccNo: 0001104659-25-065972 Size: 365 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits